Seelos Therapeutics, Inc. · OTC:SEELQ
Seelos Therapeutics — Technical Presentation (March 2024)
8 slides from Seelos Therapeutics's technical presentation, Mar 19, 2024
Slide 1: SLS-005 ALS Top-Line Data March 2024
SEELOS THERAPEUTICS SLS - 005 ALS Top - Line Data March 2024 “We are a company focused on achieving the most efficient development of products that address significant unmet needs in CNS disorders and in rare diseases”
Slide 2: Forward-Looking Statements
FORWARD - LOOKING STATEMENTS This corporate presentation includes certain forward - looking statements within the meaning of Section 21E of the Securities Exch ange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These forward - looking statements include, but are
Slide 3: ALS Prevalence and Approved Therapies
3 ALS Prevalence and Approved Therapies Edaravone (RADICAVA ® ) Approved after running a second Phase 3 study utilizing post - hoc analysis https://pubmed.ncbi.nlm.nih.gov/28522181/ ALS has a global prevalence of at least 200,000 people • 30,000 in US 1 and 30,000 in EU and UK 2 1. https://www.cdc.g
Slide 4: Regimen E (RGE) – Three Datasets Prespecified for Analysis
4 SLS - 005 (IV Trehalose) is Regimen E (RGE) – Three Datasets Prespecified for analysis Primary Analysis Prespecified Dataset SLS - 005 IV Trehalose Placebo Limitation(s) Full Analysis Set (FAS) n= 120 n=41 + n=163 (shared placebo) 1. Regimen Placebo ~ Shared placebo 2. Primary Analysis ~ Sensitivi
Slide 5: Sensitivity of primary analysis result to each dataset in Regimen E
5 Sensitivity of primary analysis result to each dataset in Regimen E (RGE) SLS - 005 IV Trehalose Consistency: Primary ≠ Sensitivity Analysis 22% Slowing of Function and Mortality Primary Analysis Model Full Analysis Set (FAS) SLS - 005 IV Trehalose (as envisioned) ERF Set – Sensitivity Analysis Po
Slide 6: ALSFRS-R Change from Baseline vs Approved ALS Treatments
6 - 5.01 - 7.00 - 6.70 - 4.80 - 7.50 - 8.10 - 9.62 - 6.42 -10.00 -9.00 -8.00 -7.00 -6.00 -5.00 -4.00 -3.00 -2.00 -1.00 0.00 RADICAVA QALSODY RELYVRIO SLS-005 (IV Trehalose) ALSFRS - R Change from Baseline SLS - 005 vs Approved ALS Treatments For illustrative purposes only. No head - to - head trials
Slide 7: Safety Endpoints
7 Safety Endpoints • Safety Endpoints – TEAE • Analysis set – STF
Slide 8: Head-to-Head Healey Platform Trial Data
8 - 8% 2% 2% 1% 13% 22% -12% -7% -2% 3% 8% 13% 18% 23% A B C D E ERF Healey Platform Trial Regimens SLS - 005 Trehalose has the best data of all regimens (A to E) completed so far Head - to - Head Healey Platform Trial Data % Change vs Placebo Function & Mortality Increased Treatment Benefit SLS - 0
Seelos Therapeutics — Technical Presentation (March 2024) on 6ix